Vaccine News and Research

Latest Vaccine News and Research

Discovery may yield new strategies for blocking malaria transmission

Scientists studying the Anopheles gambiae mosquito - the main vector of malaria - have found that when the mosquito takes a blood meal, that act triggers two enzymes to form a network of crisscrossing proteins around the ingested blood.

15 Mar 2010

SafeMinds: Government refusal to compensate vaccine-injured children casts doubt on the integrity of national immunization program

Autism and mercury advocacy organization SafeMinds regrets today's ruling by the U.S. Court of Federal Claims against three families who argued that vaccines which contained the mercury-based preservative thimerosal contributed to their child's autism.

15 Mar 2010

GAVI Alliance reaches agreement with drugmakers on reduced-price pneumococcal vaccines

Several drugmakers have reached an agreement "to supply up to 200 million doses a year of cut-price pneumococcal vaccines to developing nations," according to GAVI Alliance, Reuters reports.

15 Mar 2010

ampliPHOX detection technology of InDevR in beta site-testing in anticipation of upcoming product launch

InDevR, developer of advanced life science products, announced that its ampliPHOX Colorimetric Detection Technology is being beta site-tested in anticipation of an upcoming product launch. The original intellectual property was licensed from the University of Colorado at Boulder.

12 Mar 2010

BeaconEquity.com: BPAX incurs net loss of $6.4M for quarter ended September 30, 2009

BeaconEquity.com announces an investment report featuring biotechnology company BioSante Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

12 Mar 2010

Advaxis develops long-term, room temperature, storage-stable form of its vaccines

Advaxis, Inc., the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company has developing a long-term, room temperature, storage-stable form of its vaccines. This would replace the current requirement to keep the product frozen at -70o C before use.

12 Mar 2010

Baxter International, DVC present Phase III clinical efficacy data for PREFLUCEL

Baxter International Inc., in conjunction with DynPort Vaccine Company LLC, a CSC Company, today presented Phase III study data measuring the clinical efficacy for PREFLUCEL, a trivalent seasonal influenza candidate vaccine. PREFLUCEL is made using Baxter’s Vero cell culture platform and does not contain an adjuvant or preservatives. The data were presented at the International Congress on Infectious Disease (ICID) in Miami, Florida.

From Baxter International Inc. 12 Mar 2010

WHO welcomes Gates Foundation support in advancing global vaccine efforts

WHO welcomes the Bill & Melinda Gates Foundation pledge of US$ 10 billion over the next ten years to accelerate global vaccine efforts.

12 Mar 2010

HTDS receives Registration Certificate for MEVAC-Vari vaccine in Guatemala

Hard to Treat Diseases and its subsidiary Mellow Hope announce that the company received Registration Certificate for its MEVAC-Vari vaccine in Guatemala.

12 Mar 2010

In addition to anal and cervical cancer, HPV can also cause head and neck cancer

The Human Papillomavirus (HPV) is the causative agent responsible for most cases of cervical cancer, but is also associated with several other types of cancer.

12 Mar 2010

Positive results from BioSante Pharmaceuticals' GVAX Leukemia vaccine human clinical study

BioSante Pharmaceuticals, Inc. today announced positive results of a human clinical study that show that its GVAX Leukemia vaccine may be able to reduce or eliminate the last remaining cancer cells in some chronic myeloid leukemia (CML) patients taking the drug Gleevec (imatinib mesylate).

11 Mar 2010

iReminder’s white paper highlights key developments in HPV vaccine compliance and marketing efforts

Automated reminder and follow-up calls for HPV vaccinations increase adherence rates from 5% to over 20%, according to a new white paper published by iReminder, LLC. The Scotland National Health Service is the leader in HPV vaccination compliance, with rates as high as 92% for the first dose and 87.8% for the second dose. The laggard is Mississippi, USA where HPV vaccination rates are as low as 15.8%.

11 Mar 2010

Investigators develop new mathematical approach to analyze molecular data

Investigators have developed a new mathematical approach to analyze molecular data derived from complex mixtures of immune cells. This approach, when combined with well-established techniques, readily identifies changes in small samples of human whole blood, and has the potential to distinguish between health and disease states.

11 Mar 2010

Great Point and Deerfield invest in BioSante Pharmaceuticals

BioSante Pharmaceuticals, Inc. today announced the closing of the sale, directly to funds affiliated with two institutional investors, of an aggregate of approximately 10.4 million shares of BioSante’s common stock and warrants to purchase up to approximately 5.2 million shares of its common stock, resulting in gross cash proceeds to BioSante of $18 million.

11 Mar 2010

ImmunoCellular Therapeutics' dendritic cell-based vaccination with CSCs demonstrates survival benefits

ImmunoCellular Therapeutics, Ltd. announced today that its dendritic cell-based vaccination with cancer stem cells demonstrated a statistically significant survival benefit in a preclinical animal model of glioblastoma.

11 Mar 2010

PBI and TDI announce strategic licensing and collaborative research and development agreement

Pressure BioSciences, Inc. and Target Discovery, Inc.,, today announced a strategic product licensing, manufacturing, co-marketing, and collaborative research and development agreement. Under the terms of the Agreement, PBI has been licensed by TDI to manufacture and sell a highly innovative line of chemicals used in the preparation of tissues for scientific analysis.

11 Mar 2010

Nabi Biopharmaceuticals closes exclusive option and license agreement for NicVAX with GSK

Nabi Biopharmaceuticals announced today that the closing requirements set forth in the exclusive option and license agreement for NicVAX® (Nicotine Conjugate Vaccine), dated November 13, 2009 with GlaxoSmithKlineBiologicals S.A. have been met and the companies have closed the agreement.

11 Mar 2010

Eureka Genomics announces closing of $3.7M private financing round

Eureka Genomics today announced the closing of a $3.7 million private financing round whose participants included private individuals and undisclosed angel investors. The proceeds will further discovery research aimed at identifying novel microorganisms associated with specific cancers and other important diseases, as well as help grow Eureka Genomics’ high-throughput sequencing and bioinformatics service business on a global basis.

11 Mar 2010

Polio immunization campaign begins across West and Central Africa

More than 85 million children under five years old will be immunized against polio in 19 countries across West and Central Africa in a massive example of cross-border cooperation aimed at stopping a year-long polio epidemic.

10 Mar 2010

Bavarian Nordic' Annual Report 2009

Today Bavarian Nordic published the company's Annual Report 2009. The report is available on the company's website: www.bavarian-nordic.com

10 Mar 2010

Vaccine News and Research

Latest Vaccine News and Research

Discovery may yield new strategies for blocking malaria transmission

SafeMinds: Government refusal to compensate vaccine-injured children casts doubt on the integrity of national immunization program

GAVI Alliance reaches agreement with drugmakers on reduced-price pneumococcal vaccines

ampliPHOX detection technology of InDevR in beta site-testing in anticipation of upcoming product launch

BeaconEquity.com: BPAX incurs net loss of $6.4M for quarter ended September 30, 2009

Advaxis develops long-term, room temperature, storage-stable form of its vaccines

Baxter International, DVC present Phase III clinical efficacy data for PREFLUCEL

WHO welcomes Gates Foundation support in advancing global vaccine efforts

HTDS receives Registration Certificate for MEVAC-Vari vaccine in Guatemala

In addition to anal and cervical cancer, HPV can also cause head and neck cancer

Positive results from BioSante Pharmaceuticals' GVAX Leukemia vaccine human clinical study

iReminder’s white paper highlights key developments in HPV vaccine compliance and marketing efforts

Investigators develop new mathematical approach to analyze molecular data

Great Point and Deerfield invest in BioSante Pharmaceuticals

ImmunoCellular Therapeutics' dendritic cell-based vaccination with CSCs demonstrates survival benefits

PBI and TDI announce strategic licensing and collaborative research and development agreement

Nabi Biopharmaceuticals closes exclusive option and license agreement for NicVAX with GSK

Eureka Genomics announces closing of $3.7M private financing round

Polio immunization campaign begins across West and Central Africa

Bavarian Nordic' Annual Report 2009

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Vaccine News and Research

Latest Vaccine News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in